Global Longlife Hospital and Research Limited (GLHRL) Fair Value & Analysis
Healthcare · IN · Market cap ₹114M
Fair value as of: Jul 5, 2026
From 1 valuation models · updated today
Share price −14.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹9.77 – ₹26.40 · fair‑value band ₹12.75 – ₹24.15 · the ₹10.88 price screens below the ₹19.32 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Global Longlife Hospital and Research Limited (GLHRL) currently trades at ₹10.88, while our model-based Fair Value estimate is ₹19.32 — implying the stock looks roughly 77.6% undervalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at ₹52.0K. It earns a return on equity of -6.8%. Net debt stands at ₹124M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹12.75 (bear case) to ₹24.15 (bull case); at ₹10.88, the current price sits below that range. The share trades about 59% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside — at 78%, GLHRL screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Global Longlife Hospital and Research Limited, a multispecialty hospital, provides medical and allied services in India. It offers medical services, such as oncology, ophthalmology, allergy and immunology, pain management, pulmonology, anaesthesiology, cardiology, dermatology, critical care, diabetes and endocrinology, GI medicine, gynecology, infectious disease, nephrology, and neurology; and surgical services, including CVTS, joint replacement orthopaedics, spine surgery, general surgery, onco surgery, GI surgery, neurosurgery, ENT, plastic surgery, trauma centre, urology, laparoscopic surgery, gynaecology, dental surgery, and vascular surgery. The company also provides radiology services consisting of mammography, CT scan, X-ray, ultrasound, endoscopy, and sonography; pathology services, including microbiology, biochemistry, clinical pathology, cyto pathology, haematology, and serology; and other services comprising dialysis, pharmacy, ambulance, dietary, and physiotherapy …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Global Longlife Hospital and Research Limited reported revenue of ₹0 in FY2026 versus ₹328M in FY2022. Reported net income was −₹17.2M in FY2026.
Is GLHRL fairly valued? → Check now
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.47 | $8.55 | -25% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.71 MYR | 4.87 MYR | -44% |
| IHHHF IHHHF | $1.71 | $1.17 | -32% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.76 | R$30.33 | -7% |
| Tenet Healthcare Corporation THC | $162.06 | $282.55 | +74% |
| Fresenius Medical Care AG FMS | $23.59 | $34.71 | +47% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,489 | ₹2,128 | -75% |
| DaVita Inc DVAI34 | R$1,030 | R$1,096 | +7% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Global Longlife Hospital and Research Limited (GLHRL) undervalued?
What is the fair value of GLHRL?
What is the quality score of GLHRL?
What is the revenue of Global Longlife Hospital and Research Limited (GLHRL)?
What is the net profit margin of GLHRL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.